Click Therapeutics develops prescription digital therapeutics (regulated software-as-medical-treatment mobile applications) that deliver therapeutic interventions and integrate with pharmacotherapy, supported by clinical trials and regulatory submissions.
Published Aug 15, 2026
Click Therapeutics is not typically listed in enterprise B2B software review platforms (for example, G2 or TrustRadius) under its product names in a way that yielded substantive product review pages in searches. As a result, this section relies more on App Store reviews for consumer-facing products, community discussions, and press coverage for adoption and criticism.
A Reddit thread includes users noting modest symptom improvement and that structured digital activity beyond medication or psychotherapy can support motivation. This is anecdotal and not a substitute for controlled clinical evidence, but it reflects some patients' framing of the product's value.
Public employer review sites show ratings roughly in line with comparable organizations based on limited samples; these signals are workforce sentiment indicators rather than product efficacy measures.
Company materials describe a multi-week multicenter remote double-blinded randomized controlled trial (the Mirai study) with several hundred participants comparing Rejoyn to a sham control app; reported improvements were observed on standard depression scales and no treatment-related adverse events were reported. Buyers should request full trial publications and regulatory summaries to assess effect sizes, clinical significance, and methodological details.
Company announcements report Phase III results with reported between-group differences and claims of statistical significance. These announcements are company press releases and partnership communications; independent verification via peer-reviewed publication, clinical study reports, or regulatory documents is recommended before treating results as definitive.
The digital therapeutics sector has demonstrated commercialization and reimbursement risks, as evidenced by the bankruptcy and asset sale of a prominent DTx vendor. That event is frequently cited as a category caution and informs commercial risk assessments for other DTx companies.
Get a comprehensive analysis of Click Therapeutics including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →From public app store listings for Rejoyn:
Interpretation (cautious): App Store reviews suggest that the user experience is positive for some individuals, while other users raise strong critiques about time-limited access and prescription/paywall friction. These critiques are relevant because adherence and long-term reinforcement are central to behavioral interventions.
The company's product pages and press materials describe randomized controlled trials and clinical outcomes for several products, including reported reductions in clinical endpoints for cardiometabolic and mental health indications. These vendor-published summaries are initial signals of clinical activity, but prospective buyers should review full trial reports, peer-reviewed publications, and regulatory materials to evaluate endpoints, effect sizes, blinding, attrition, and clinical meaningfulness.
Click Therapeutics develops prescription digital therapeutics (PDT/DTx) that are regulated software-as-medical-treatment mobile applications and approaches that combine software with drugs. The company's products are intended to be prescribed by clinicians, used by patients on smartphones, and supported by clinical trials. The software delivers therapeutic interventions (for example, neurobehavioral/CBT-style modules and training tasks) either as a regulated device therapy or as an adjunct to pharmacotherapy.
A key market reality: Click is more comparable to a medical device or biotech developer than a typical SaaS vendor—evaluation criteria generally focus on regulatory status, clinical evidence, reimbursement pathways, and deployment into clinical workflows rather than feature checklists.